Bristol-Myers blueprints a 2,500-worker campus in New Jersey

Bristol-Myers Squibb ($BMY) is gearing up to build a 2,500-employee campus in New Jersey, following the biopharma trend of ditching far-flung outposts in favor of collaboration-encouraging hubs.

The new space, in Lawrenceville, will be a 650,000-square-foot complex, expected to open its doors by the end of 2016, the company said. Bristol-Myers' new shop will consolidate two existing offices in nearby Plainsboro and West Windsor, according to the company, bringing those employees under one roof with added room to grow.

Bristol-Myers touts its new space as part of an over-arching plan to modernize its workplaces and better encourage the free flow of ideas. The plan is to encourage nimble collaboration by removing the walls between employees, literally through its design and figuratively via widespread videoconferencing, the company said.

"Our new campus will create a dynamic and modern workplace to advance the important work that our employees are doing to discover, develop and deliver innovative medicines for patients with serious diseases," CEO Lamberto Andreotti said.

Bristol-Myers' move dovetails with a trend among the world's largest drugmakers, who are moving toward the hub model, both in R&D and administrative functions. AstraZeneca ($AZN) is the most recent to adopt the strategy, plotting to pool most of its research operation in a single Cambridge, U.K., campus, mirroring similar efforts from Pfizer ($PFE), Roche ($RHHBY), Merck KGaA and others.

- read the statement

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

U.K.-based alpha-synuclein biotech Wren will partner with Japanese pharma Eisai to seek out new ways of targeting neuro disorders.

As Moderna continues to drip-feed the latest data from its late-stage COVID-19 vaccine effort, it has updated the shot’s efficacy figure.

Two research teams have discovered drug combinations that may make it possible to translate CAR-T cell therapies to solid tumors.